Association for Accessible Medicines

12/15/2025

Brian Reid Brings Strategic Insight to Access! 2026

Join Brian Reid, Founder and Principal of Reid Strategic and Senior Fellow at Tufts’ Center for the Evaluation of Value and Risk in Health, for a fireside chat with Alex Keeton, Executive Director of the Biosimilars Council and AAM’s Senior VP of Policy.

Together, they’ll explore how generics and biosimilars can shape the conversation on value, access, and affordability—and how strategic storytelling can move the needle in Washington and beyond.

Don’t miss this must-see session at Access! 2026—
where insight meets impact. Register now: https://access.accessiblemeds.org

12/12/2025

DRUG SHORTAGES HAMPER PATIENT CARE! Continued drug shortages are a result of unsustainably low pricing, increases in government policies – including tariffs – that further compound market dynamics, and regulatory challenges. Learn more in the : https://accessiblemeds.org/resources/blog/2025-savings-report

12/08/2025

PBMs DELAY PATIENT SAVINGS! First generics, or medicines approved by FDA as the first competitor to the brand drug, often face challenges in market adoption. Slower adoption for first generics is driven in part by slower coverage decisions of PBMs and health plans. These entities benefit from rebates on high-priced brand drugs, even though patients would save through lower-cost generics and biosimilars. Learn more: https://accessiblemeds.org/resources/blog/2025-savings-report

12/05/2025

and provide critical savings throughout the U.S. healthcare system and are particularly valuable to Medicare and the patients they serve. In 2024, the use of generics saved $142 billion in Medicare and $62 billion in Medicaid. Learn more about savings from this essential industry and what can be done to ensure America’s patients can thrive with access to these lower-cost medications: : https://accessiblemeds.org/resources/blog/2025-savings-report

12/02/2025

The average market entry of a first generic is between 12 and 14 years; and approximately 18 years for a first biosimilar. One thing is clear: The Inflation Reduction Act (IRA) harms generic and biosimilar medicine competition and it must be amended– especially to promote more robust biosimilar competition. https://accessiblemeds.org/resources/blog/2025-savings-report

11/20/2025

Right now, little is being done to infuse sustainability into the generic marketplace. Compared to 30 years ago, generic drugs are launching at lower prices and bottoming out at lower prices. This generic deflation puts savings and America’s patients in jeopardy. Learn what can be done to help safeguard the savings for patients AND help strengthen the industry: https://accessiblemeds.org/resources/blog/2025-savings-report

11/17/2025

Comprising only 1.2 percent of total U.S. healthcare spending in 2024, generic medicines saved Americans $467 billion—providing patients the health and financial outcomes necessary to thrive. https://accessiblemeds.org/resources/blog/2025-savingsreport

11/14/2025

A decade after the first entered to the U.S. market, $56.2 billion have been saved by the healthcare system and 3.3 billion additional days of patient care have been possible. But due to harmful policies that impeded biosimilar uptake, we are currently experiencing a biosimilar void. Policymakers must ACT NOW to safeguard enormous benefits to Americans—$20.2 billion in 2024, alone. MORE: https://accessiblemeds.org/resources/blog/2025-savings-report

11/10/2025

Generic medicines give America's patients the confidence to thrive! Last year, comprised 90% of all prescriptions filled, but only 12% of prescription spending. In sharp contrast, brand drugs supported patients less often— making up only 10% of prescriptions filled but adding up to 88% of the total drug spend. Learn more about what makes generic medicines unique in AAM’s : https://accessiblemeds.org/resources/blog/2025-savings-report

11/06/2025

In 2024, & saved America’s patients and the U.S. healthcare system $467 billion—and $3.4 trillion in the past 10 years. Learn more, including what can be done to help safeguard this important industry: https://accessiblemeds.org/resources/blog/2025-savings-report

11/04/2025

10/28/2025

Read our Day 1 Recap: https://accessiblemeds.org/resources/blog/grxbiosims-2025-day-1-recap/